Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.35 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.35 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 3/20 | 0.35 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24305059 | 1.00 | USP2 (0.40) | USP2CNR2ALDH1A1HPGDLPAR1 | |
| SCHEMBL25335620 | 0.85 | LPAR3 (0.58) | LPAR1LPAR3LPAR2 | |
| SCHEMBL25335623 | 0.85 | LPAR3 (0.58) | LPAR1LPAR3LPAR2 | |
| SCHEMBL24304953 | 0.84 | CNR2 (0.41) | USP2CNR2ALDH1A1HPGDCNR1 | |
| SCHEMBL31069869 | 0.84 | ALDH1A1 (0.34) | ALDH1A1HPGDPLA2G2A | |
| SCHEMBL31129694 | 0.82 | PLA2G2A (0.42) | ALDH1A1HPGDLPAR1LPAR3LPAR2 | |
| SCHEMBL24305074 | 0.82 | CNR2 (0.39) | USP2CNR2ALDH1A1HPGDLPAR1 | |
| SCHEMBL24304737 | 0.82 | PLA2G2A (0.33) | ALDH1A1HPGDLPAR1LPAR3LPAR2 | |
| SCHEMBL24305057 | 0.81 | USP2 (0.42) | USP2ALDH1A1HPGDLPAR1LPAR3 | |
| SCHEMBL29020843 | 0.81 | USP2 (0.42) | USP2ALDH1A1HPGDLPAR1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118591377-A | Antiviral prodrugs, intermediate and long acting formulations and methods | 加利福尼亚大学董事会 | 2024-09-03 | — | — | CN | disclosed |